alpha 2 -delta site Inhibitors
1 drugsAbout alpha 2 -delta site
The alpha 2-delta (α2δ) site is an auxiliary subunit of voltage-gated calcium channels (VGCCs), modulating neuronal excitability and neurotransmitter release. Targeting this site can modulate calcium channel function, reducing neuronal hyperexcitability associated with various pain conditions.
The α2δ site is a pharmacological target for pain management, evidenced by one FDA-approved drug. Currently, there is no genetic evidence data available linking the α2δ site to specific diseases, representing an area for further research.
LYRICA (pregabalin) is the only FDA-approved drug targeting the α2δ site, indicated for 6 conditions and marketed by CP PHARMS. It is a small molecule, highlighting the potential for other modalities to be explored.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Hepatocellular Cancer with only 1 trials.
Top alpha 2 -delta site Drugs
CP PHARMS is the only company with an approved drug targeting this site.
The lack of competition suggests a high barrier to entry or an untapped market.
alpha 2 -delta site Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 2 -delta site, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
alpha 2 -delta site Clinical Trials 265 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 43 | 40 | 0 | 3 | 100% |
| Phase 2 | 62 | 40 | 14 | 7 | 74% |
| Phase 3 | 65 | 51 | 12 | 2 | 81% |
| Phase 4 | 95 | 71 | 17 | 7 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved alpha 2 -delta site drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting alpha 2 -delta site. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
alpha 2 -delta site Drug Approval Timeline (2004 - 2004)
The first and only drug, LYRICA, was approved in 2004.
The approval timeline suggests a saturated market or a lack of innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 124 clinical trials targeting alpha 2 -delta site.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities